As we close in on the end of 2022, we’ve had the privilege to interview some amazing people who are doing great work with drug discovery.   Join Gina Mullane and Todd Poley as we reflect on some of the memorable moments and guests from this season, including an update on Amylyx Pharmaceuticals’ new ALS treatment, Chris Claussen’s discussion on the positive impacts of psychedelic drugs, and the work of Project ALS to develop a treatment for this crippling disease. On behalf of our entire team, thank you for listening this year. We hope you’ll join us for an exciting lineup of remarkable stories set to premiere in 2023.Show Notes:

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS 

Alzheimer’s Disease Studies  

In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis 

Are Psychedelics the Next Approach to Treating Mental Health Disorders? 

FIRST PERSON LAUNCHES INNOVATIVE PRECISION-TARGETED COGNITIVE SUPPLEMENTS TO ACTIVATE THE FULL POTENTIAL OF HUMAN COGNITION 

The Hermstad Legacy: Advances in Treatments for ALS  

Project ALS